​​HR-positive, HER2-negative, inoperable locally advanced or metastatic breast cancer​ research hub

A Multicenter, Randomized, Double-Blind, Double-Dummy, Phase III Study to Evaluate the Efficacy and Safety of Letrozole SIE Compared to Femara® (both in Combination with the CDK4/6 Inhibitor Ribociclib) in Postmenopausal Women with HR-Positive, HER2-Negative, Inoperable Locally Advanced or Metastatic Breast Cancer (SIE-3)

This clinical trial looks at a new injection form of letrozole, a common hormone therapy for advanced breast cancer. Researchers want to see if this long-acting injection works just as well as daily tablets at slowing cancer growth, while also comparing side effects like joint and muscle aches.